Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label Study
Authors:
- Denis MullemanDMDenis Mulleman
- Emilie DucourauEDEmilie Ducourau
- Francine LauféronFLFrancine Lauféron
- Delphine Chu Miow LinDLDelphine Chu Miow Lin
- Hervé WatierHWHervé Watier
- Philippe GoupillePGPhilippe Goupille
- Gilles PaintaudGPGilles Paintaud
- 1 August 2011
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 33 (4) , 411-416
Abstract
Infliximab is a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha and which is approved for refractory spondyloarthritis (SpA). Individual adjustment of infliximab dosage may help to improve the therapeutic response in SpA. We investigated whether a knowledge of infliximab serum concentration modifies physician decision and improves the control of disease activity in SpA. Thirty-two patients routinely treated with infliximab were included in an observational open-label study. On visit 1 (V1), according to disease activity, a preliminary therapeutic decision was selected among 4 therapeutic options (ie, decrease, increase, maintain the dosage of infliximab, or switch over for another treatment), and a blood sample was collected to measure infliximab trough serum concentration. The final therapeutic decision, based on both disease activity and infliximab serum concentration assessed at V1, was applied at the following infusion (V2). Clinical and biological evaluations were performed at V3 and V4 and compared with those at V1. The measurement of infliximab trough concentration modified the therapeutic decision for 10 patients (31%). For both patients with increased or decreased infliximab dosage at V2, median Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was similar at V3 or V4 as compared with that at V1. However, a trend for an inverse relationship between infliximab serum concentrations and BASDAI was observed. Knowledge of infliximab trough concentration modified the therapeutic decision for SpA patients with predominantly axial symptoms but did not improve the control of disease activity as estimated by the BASDAI.Keywords
This publication has 18 references indexed in Scilit:
- Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitisScandinavian Journal of Rheumatology, 2010
- Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 updateJoint Bone Spine, 2007
- Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formationAnnals of the Rheumatic Diseases, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of InfliximabTherapeutic Drug Monitoring, 2006
- Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre studyRheumatology, 2005
- Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2005
- Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)Arthritis & Rheumatism, 2005
- Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trialThe Lancet, 2002
- Randomized double‐blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathyArthritis & Rheumatism, 2002